These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31191001)

  • 1. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    Jiang X; Li W; Li X; Bai H; Zhang Z
    Cancer Manag Res; 2019; 11():4371-4390. PubMed ID: 31191001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
    Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in ovarian cancer.
    Ledermann JA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
    Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    Faraoni I; Graziani G
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP Inhibition in Cancer: An Update on Clinical Development.
    Sachdev E; Tabatabai R; Roy V; Rimel BJ; Mita MM
    Target Oncol; 2019 Dec; 14(6):657-679. PubMed ID: 31625002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
    Ohmoto A; Yachida S
    Onco Targets Ther; 2017; 10():5195-5208. PubMed ID: 29138572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
    Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
    Luo J; Ou S; Wei H; Qin X; Jiang Q
    Front Oncol; 2022; 12():815265. PubMed ID: 35756600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the use of PARP inhibitor therapy for breast cancer.
    McCann KE; Hurvitz SA
    Drugs Context; 2018; 7():212540. PubMed ID: 30116283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
    Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in ovarian cancer.
    Franzese E; Centonze S; Diana A; Carlino F; Guerrera LP; Di Napoli M; De Vita F; Pignata S; Ciardiello F; Orditura M
    Cancer Treat Rev; 2019 Feb; 73():1-9. PubMed ID: 30543930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.